AD HOC

PUBLIC DISCLOSURE OF INSIDE INFORMATION PURSUANT TO ARTICLE 17 OF REGULATION (EU) NO. 596/2014

Pentixapharm Holding AG Resolves on Rights Issue with an Offering Volume of up to Approximately EUR 20.4 Million; Major Shareholder Eckert Wagniskapital Commits to Fully Exercise Its Subscription Rights

Berlin, July 1, 2026 – The Management Board of Pentixapharm Holding AG, Berlin, (ISIN DE000A40AEG0, WKN A40AEG) ("Company") today resolved, with the approval of the Supervisory Board, to increase the Company’s share capital against cash contributions from currently EUR 24,795,477.00 by up to EUR 11,020,212.00 to up to EUR 35,815,689.00 by issuing up to 11,020,212 new registered no-par value shares, making partial use of the Company’s Authorized Capital.

The new shares will carry full dividend rights as from January 1, 2026 and are intended to be offered to the Company’s existing shareholders by way of indirect subscription rights. The subscription ratio will be 9:4, meaning that nine existing shares entitle their holder to subscribe for four new shares. Subscription rights for fractional amounts are excluded. The subscription price per new share (“Subscription Price”) is EUR 1.85. This represents a discount of approximately 21% to the Xetra closing price of the share on June 30, 2026.

The subscription period is expected to begin on July 7, 2026 and to end on July 21, 2026. Shareholders are also expected to be given the opportunity to subscribe, at the subscription price, for additional new shares in excess of their statutory subscription rights by way of an oversubscription offer. New shares not subscribed for may be offered to selected qualified investors in a private placement at a price at least equal to the subscription price. The rights issue is being accompanied by BankM AG.

The Company’s major shareholder, Eckert Wagniskapital und Frühphasenfinanzierung GmbH, which holds just under 36% of the shares in Pentixapharm Holding AG, has committed to the Company to fully exercise its subscription rights in the rights offering.

Assuming full placement of all new shares, the Company would receive gross issue proceeds of up to approximately EUR 20.4 million. After deduction of estimated transaction costs, net proceeds of approximately EUR 19.8 million are expected, assuming full subscription.

The Company intends to use the net proceeds primarily to finance key steps of the PANDA Phase 3 study, as well as the Company’s further corporate development and expansion in the U.S. market. The PANDA Phase 3 study evaluates [⁶⁸Ga]Ga-PentixaFor, the Company’s lead CXCR4-targeted diagnostic program, in patients with difficult-to-control hypertension due to underlying primary aldosteronism. The registrational trial is intended to further develop a novel imaging-based approach to patient subtyping designed to support treatment decisions between surgical and medical management.

A further portion of the net proceeds is intended to be used to continue preparing clinical development activities and to strengthen the Company’s manufacturing and supply infrastructure. These measures are intended to support the late-stage clinical development of the Company’s programs and further build the foundation for potential future commercialization. In addition, the Company intends to use proceeds to further develop its CXCR4-based theranostic platform, including PentixaTher in hematologic oncology indications. Finally, the proceeds are intended to strengthen the Company’s equity base and to fund general corporate purposes and working capital beyond the first quarter of 2027.

Further details of the rights issue will be set out in the subscription offer, which is expected to be published in the electronic German Federal Gazette (elektronischer Bundesanzeiger) on July 3, 2026.

No securities prospectus will be published for the public offering of the new shares or for their admission to trading on the regulated market of the Frankfurt Stock Exchange, with simultaneous admission to the sub-segment of the regulated market with additional post-admission obligations (Prime Standard). In accordance with Regulation (EU) 2017/1129, the Company will publish a document containing the information required under Annex IX to Regulation (EU) 2017/1129. The Annex IX document is expected to be available on the Company’s website in the Investors section as from July 3, 2026.

July 1, 2026

Pentixapharm Holding AG, Berlin

The Management Board

Contact: ir@pentixapharm.com

Important Notice: This announcement does not constitute an offer to sell or a solicitation of an offer to purchase or subscribe for any securities. Any public offering will be made solely on the basis of the subscription offer to be published and the Annex IX document. This announcement is not intended for publication, distribution or release in or into the United States of America, Australia, Canada, Japan or any other jurisdiction where such publication, distribution or release would be unlawful.

The new shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("Securities Act"), and may not be offered or sold in the United States of America or to, or for the account or benefit of, U.S. persons absent registration under, or an applicable exemption from the registration requirements of, the Securities Act. There will be no public offering of the shares in the United States of America.

2357930  01-Jul-2026 CET/CEST